시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
폐동맥 고혈압 시장 규모, 점유율, 성장 분석 : 약물 종류별, 유형별, 투여 경로별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Pulmonary Arterial Hypertension Market Size, Share, Growth Analysis, By Drug Class (Endothelin Receptor Antagonists, PDE-5 Inhibitors), By Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드 : 1630622
리서치사 : SkyQuest
발행일 : 2025년 01월
페이지 정보 : 영문 157 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,636,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,932,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,229,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

폐동맥 고혈압 세계 시장 규모는 2023년 77억 9,000만 달러로 예측 기간(2025-2032년) 동안 CAGR 5.3%, 2024년 82억 달러에서 2032년 124억 달러로 성장할 것으로 예상됩니다.

폐동맥 고혈압(PAH) 시장은 유병률 증가, 희귀질환 치료제 개발에 대한 정부 지원 강화, 노인 인구 증가 등 몇 가지 주요 요인에 의해 성장할 것으로 예상됩니다. 체계적인 검토에 따르면, PAH의 유병률은 인구 10만 명당 0.4%에서 1.4%이며, 고혈압을 앓고 있는 30-79세 인구는 전 세계적으로 약 12억 8,000만 명으로 추산되며, 주로 중저소득 국가에서 주로 발생하며, WHO는 2010년부터 2030년까지 고혈압 유병률을 33% 감소시킬 것을 목표로 하고 있습니다. 고혈압 유병률을 33% 감소시키겠다는 중요한 목표를 설정하고 이 분야에 대한 더 많은 연구와 치료법의 필요성을 강조하고 있습니다. 이러한 연구 결과를 종합하면, PAH 치료의 진전이 기대됩니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

폐동맥 고혈압 시장 규모 : 약물 종류별

폐동맥 고혈압 시장 규모 : 유형별

폐동맥 고혈압 시장 규모 : 투여 경로별

폐동맥 고혈압 시장 규모 : 유통 채널별

폐동맥 고혈압 시장 규모

경쟁 정보

주요 기업 개요

결론과 추천사항

KSM
영문 목차

영문목차

Global Pulmonary Arterial Hypertension Market size was valued at USD 7.79 billion in 2023 and is poised to grow from USD 8.2 billion in 2024 to USD 12.4 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The pulmonary arterial hypertension (PAH) market is poised for growth due to several key factors, including the increasing incidence of the disease, enhanced government support for orphan drug development, and a growing elderly population. A systematic review highlighted the prevalence of PAH, indicating it affects between 0.4% and 1.4% of individuals per 100,000, with an estimated 1.28 billion people aged 30-79 globally affected by hypertension, predominantly in low- and middle-income countries. The WHO has set significant targets to reduce hypertension prevalence by 33% from 2010 to 2030, emphasizing the need for further research and treatment options in this area. Collectively, these insights set a promising stage for advancements in the PAH treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segmental Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

The global pulmonary arterial hypertension (PAH) market is experiencing significant growth due to the increasing prevalence of this rare yet progressive condition, which is characterized by elevated blood pressure in the arteries leading to the lungs. Factors contributing to this rise include aging populations, a growing incidence of risk factors such as obesity, and advancements in diagnostic techniques. Consequently, there is a heightened demand for effective PAH treatments. Furthermore, the development of innovative therapies, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has bolstered market growth due to their improved efficacy and safety profiles, ultimately driving greater patient interest and need for these medications.

Restraints in the Global Pulmonary Arterial Hypertension Market

The global market for pulmonary arterial hypertension (PAH) faces certain constraints due to the limited pool of patients affected by this rare disease. Unlike more prevalent chronic conditions, PAH has a low incidence rate, which can significantly impact the commercial potential of therapeutic drugs designed for treatment and may deter investment in research and development. Additionally, diagnosing PAH requires a series of complex tests, including echocardiography, right heart catheterization, and pulmonary function assessments. Furthermore, symptoms such as fatigue and shortness of breath are often vague and can be misattributed to other health issues, resulting in delayed or incorrect diagnoses that hinder patient access to appropriate care.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper comprehension of the disease's genetic underpinnings. Pharmaceutical companies are heavily investing in research and development initiatives aimed at discovering biomarkers that can enhance the predictability of disease progression and treatment efficacy. This trend is fostering the creation of tailored therapies that specifically address varying genetic mutations associated with PAH, thereby improving patient outcomes. As a result, the market is poised for robust growth, characterized by innovation, a focus on individualized treatment regimens, and a commitment to precision healthcare solutions.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2025-2032)

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2025-2032)

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2025-2032)

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2025-2032)

Global Pulmonary Arterial Hypertension Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기